This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dudas, R. A.
Right arrow Articles by Karron, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dudas, R. A.
Right arrow Articles by Karron, R. A.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, July 1998, p. 430-439, Vol. 11, No. 3
0893-8512/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Respiratory Syncytial Virus Vaccines

Robert A. Dudas and Ruth A. Karron*

Center for Immunization Research, Department of International Health, School of Hygiene and Public Health, and Department of Pediatrics, School of Medicine, The Johns Hopkins University, Baltimore, Maryland 21205

Respiratory syncytial virus (RSV) is the most important cause of viral lower respiratory tract illness (LRI) in infants and children worldwide and causes significant LRI in the elderly and in immunocompromised patients. The goal of RSV vaccination is to prevent serious RSV-associated LRI. There are several obstacles to the development of successful RSV vaccines, including the need to immunize very young infants, who may respond inadequately to vaccination; the existence of two antigenically distinct RSV groups, A and B; and the history of disease enhancement following administration of a formalin-inactivated vaccine. It is likely that more than one type of vaccine will be needed to prevent RSV LRI in the various populations at risk. Although vector delivery systems, synthetic peptide, and immune-stimulating complex vaccines have been evaluated in animal models, only the purified F protein (PFP) subunit vaccines and live attenuated vaccines have been evaluated in recent clinical trials. PFP-2 appears to be a promising vaccine for the elderly and for RSV-seropositive children with underlying pulmonary disease, whereas live cold-passaged (cp), temperature-sensitive (ts) RSV vaccines (denoted cpts vaccines) would most probably be useful in young infants. The availability of cDNA technology should allow further refinement of existing live attenuated cpts candidate vaccines to produce engineered vaccines that are satisfactorily attenuated, immunogenic, and phenotypically stable.

* Corresponding author. Mailing address: Center for Immunization Research, Johns Hopkins University School of Hygiene and Public Health, Hampton House 117, 624 N. Broadway, Baltimore, MD 21205. Phone: (410) 614-0319. Fax: (410) 955-2791. E-mail: rkarron{at}jhsph.edu.

Clinical Microbiology Reviews, July 1998, p. 430-439, Vol. 11, No. 3
0893-8512/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Lee, S., Miller, S. A., Wright, D. W., Rock, M. T., Crowe, J. E. Jr. (2007). Tissue-Specific Regulation of CD8+ T-Lymphocyte Immunodominance in Respiratory Syncytial Virus Infection. J. Virol. 81: 2349-2358 [Abstract] [Full Text]  
  • Rosenthal, K. S., Zimmerman, D. H. (2006). Vaccines: All Things Considered. CVI 13: 821-829 [Full Text]  
  • Asenjo, A., Rodriguez, L., Villanueva, N. (2005). Determination of phosphorylated residues from human respiratory syncytial virus P protein that are dynamically dephosphorylated by cellular phosphatases: a possible role for serine 54. J. Gen. Virol. 86: 1109-1120 [Abstract] [Full Text]  
  • Valosky, J., Hishiki, H., Zaoutis, T. E., Coffin, S. E. (2005). Induction of Mucosal B-Cell Memory by Intranasal Immunization of Mice with Respiratory Syncytial Virus. CVI 12: 171-179 [Abstract] [Full Text]  
  • Tang, R. S., MacPhail, M., Schickli, J. H., Kaur, J., Robinson, C. L., Lawlor, H. A., Guzzetta, J. M., Spaete, R. R., Haller, A. A. (2004). Parainfluenza Virus Type 3 Expressing the Native or Soluble Fusion (F) Protein of Respiratory Syncytial Virus (RSV) Confers Protection from RSV Infection in African Green Monkeys. J. Virol. 78: 11198-11207 [Abstract] [Full Text]  
  • Krempl, C., Murphy, B. R., Collins, P. L. (2002). Recombinant Respiratory Syncytial Virus with the G and F Genes Shifted to the Promoter-Proximal Positions. J. Virol. 76: 11931-11942 [Abstract] [Full Text]  
  • Jones, L. P., Zheng, H.-Q., Karron, R. A., Peret, T. C. T., Tsou, C., Anderson, L. J. (2002). Multiplex Assay for Detection of Strain-Specific Antibodies against the Two Variable Regions of the G Protein of Respiratory Syncytial Virus. CVI 9: 633-638 [Abstract] [Full Text]  
  • Schmidt, A. C., Wenzke, D. R., McAuliffe, J. M., St. Claire, M., Elkins, W. R., Murphy, B. R., Collins, P. L. (2002). Mucosal Immunization of Rhesus Monkeys against Respiratory Syncytial Virus Subgroups A and B and Human Parainfluenza Virus Type 3 by Using a Live cDNA-Derived Vaccine Based on a Host Range-Attenuated Bovine Parainfluenza Virus Type 3 Vector Backbone. J. Virol. 76: 1089-1099 [Abstract] [Full Text]  
  • Wennergren, G., Kristjansson, S. (2001). Relationship between respiratory syncytial virus bronchiolitis and future obstructive airway diseases. Eur Respir J 18: 1044-1058 [Abstract] [Full Text]  
  • Dennehy, P. H. (2001). Active Immunization in the United States: Developments over the Past Decade. Clin. Microbiol. Rev. 14: 872-908 [Abstract] [Full Text]  
  • Meissner, H. C. (2001). Uncertainty in the Management of Viral Lower Respiratory Tract Disease. Pediatrics 108: 1000-1003 [Full Text]  
  • Hall, C. B. (2001). Respiratory Syncytial Virus and Parainfluenza Virus. NEJM 344: 1917-1928 [Full Text]  
  • Schmidt, A. C., McAuliffe, J. M., Murphy, B. R., Collins, P. L. (2001). Recombinant Bovine/Human Parainfluenza Virus Type 3 (B/HPIV3) Expressing the Respiratory Syncytial Virus (RSV) G and F Proteins Can Be Used To Achieve Simultaneous Mucosal Immunization against RSV and HPIV3. J. Virol. 75: 4594-4603 [Abstract] [Full Text]  
  • Prince, G. A., Capiau, C., Deschamps, M., Fabry, L., Garcon, N., Gheysen, D., Prieels, J.-P., Thiry, G., Van Opstal, O., Porter, D. D. (2000). Efficacy and Safety Studies of a Recombinant Chimeric Respiratory Syncytial Virus FG Glycoprotein Vaccine in Cotton Rats. J. Virol. 74: 10287-10292 [Abstract] [Full Text]  
  • Teng, M. N., Whitehead, S. S., Bermingham, A., St. Claire, M., Elkins, W. R., Murphy, B. R., Collins, P. L. (2000). Recombinant Respiratory Syncytial Virus That Does Not Express the NS1 or M2-2 Protein Is Highly Attenuated and Immunogenic in Chimpanzees. J. Virol. 74: 9317-9321 [Abstract] [Full Text]  
  • Falsey, A. R., Walsh, E. E. (2000). Respiratory Syncytial Virus Infection in Adults. Clin. Microbiol. Rev. 13: 371-384 [Abstract] [Full Text]  
  • Tripp, R. A., Jones, L., Anderson, L. J., Brown, M. P. (2000). CD40 Ligand (CD154) Enhances the Th1 and Antibody Responses to Respiratory Syncytial Virus in the BALB/c Mouse. J. Immunol. 164: 5913-5921 [Abstract] [Full Text]  
  • BERSTAD, A.K. H., HOLST, J., FROHOLM, L.O., HAUGEN, I.L., WEDEGE, E., OFTUNG, F., HANEBERG, B. (2000). A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers. J Med Microbiol 49: 157-163 [Abstract] [Full Text]  
  • Sullender, W. M. (2000). Respiratory Syncytial Virus Genetic and Antigenic Diversity. Clin. Microbiol. Rev. 13: 1-15 [Abstract] [Full Text]  
  • Tripp, R. A., Moore, D., Jones, L., Sullender, W., Winter, J., Anderson, L. J. (1999). Respiratory Syncytial Virus G and/or SH Protein Alters Th1 Cytokines, Natural Killer Cells, and Neutrophils Responding to Pulmonary Infection in BALB/c Mice. J. Virol. 73: 7099-7107 [Abstract] [Full Text]  
  • Sakurai, H., Williamson, R. A., Crowe, J. E., Beeler, J. A., Poignard, P., Bastidas, R. B., Chanock, R. M., Burton, D. R. (1999). Human Antibody Responses to Mature and Immature Forms of Viral Envelope in Respiratory Syncytial Virus Infection: Significance for Subunit Vaccines. J. Virol. 73: 2956-2962 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»